Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2609421 | 0.84 | RAB9A (0.53) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL22824711 | 0.84 | MAPT (0.45) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL11883690 | 0.82 | RAB9A (0.49) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2513271 | 0.82 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL10052165 | 0.82 | KMT2A (0.58) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2609415 | 0.82 | RAB9A (0.56) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2222772 | 0.82 | ATP4A (0.49) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2754043 | 0.81 | ALDH1A1 (0.55) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL14558317 | 0.81 | RAB9A (0.50) | RAB9AMAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL24721298 | 0.79 | CCR4 (0.46) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-9809556-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | RAB9A 1816/4885MAPT 16/4885SMN1; SMN2 1/4885 |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | RAB9A 1816/4885MAPT 16/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.